This is a LLY news story, published by Investor's Business Daily, that relates primarily to Mounjaro news.
For more LLY news, you can click here:
more LLY newsFor more Mounjaro news, you can click here:
more Mounjaro newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Investor's Business Daily, you can click here:
more news from Investor's Business DailyOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Eli Lilly stock. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest revenue total news, revenue news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Eli LillyInvestor's Business Daily
•
79% Informative
Eli Lilly ( LLY ) lowered guidance for its December quarter amid slower-than-expected sales for its Zepbound and Mounjaro weight loss drugs.
The Indianapolis -based company said it expects revenue of about $13.5 billion , below consensus estimates.
Eli Lilly stock fell more than 7% to 741.22 .
VR Score
85
Informative language
92
Neutral language
42
Article tone
formal
Language
English
Language complexity
37
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
4
Source diversity
4
Affiliate links
no affiliate links